Global Laser Therapy Devices Market Strategic Research Report

Scope of the Report

The global Laser Therapy Devices market size is predicted to grow from US$ 3,522 million in 2025 to US$ 6,514 million in 2032; it is expected to grow at a CAGR of 9.2% from 2026 to 2032.

Laser therapy devices refer to a category of medical instruments that utilize photothermal effects, photochemical effects, or photobiomodulation effects generated by the interaction between laser and biological tissue to achieve disease treatment or symptom management. Since the advent of the first ruby laser in 1960, laser medicine has evolved into a comprehensive interdisciplinary field. From a technological composition perspective, laser therapy devices typically consist of a laser source, light delivery system, cooling apparatus, and control software, with core parameters including laser wavelength, output power, pulse width, and energy density. In clinical applications, laser therapy has developed three major technological branches. High-intensity laser therapy uses photothermal effects for tissue coagulation, vaporization, or cutting, transforming traditional surgical approaches. Photodynamic therapy generates cytotoxic substances through the synergistic action of photosensitizers and lasers to achieve targeted tumor treatment. Low-level laser therapy utilizes milliwatt-level lasers to stimulate physiological and biochemical responses in the body for tissue repair and pain management. Currently, laser therapy devices have expanded from ophthalmology and dermatology into urology, neurosurgery, cardiovascular intervention, and other fields, with their industrial value continuing to rise alongside the deepening of precision medicine and minimally invasive concepts.

Market Development Opportunities and Key Drivers

Femtosecond lasers, with their extremely short pulse widths and ultra-high precision, achieve attenuation-free transmission in transparent tissues while minimizing thermal damage to surrounding tissue, positioning them as the ideal technology for ophthalmic treatment. The integration of laser technology with image navigation is opening new clinical applications, with Medtronic's Visualase™ V2 system receiving FDA 510(k) clearance in June 2025, combining laser interstitial thermal therapy with real-time MRI navigation to precisely ablate intracranial lesions through an incision of just 4 millimeters. On the regulatory front, the NMPA Center for Medical Device Evaluation issued the Carbon Dioxide Laser Therapy Device Registration Review Guideline in December 2025, providing a clear registration pathway for innovative products. On the payment side, the proliferation of ambulatory surgery and enhanced recovery protocols is prompting healthcare institutions to prioritize laser devices that shorten hospital stays and reduce complication risks.

Market Challenges and Risks

Key technologies such as ultrafast lasers have yet to break foreign monopoly, with the high-end market long dominated by imported products. Data from the first three quarters of 2025 shows that laser surgical devices ranked among the top three imported products by initial registration count, predominantly Class III devices with the highest technical barriers, indicating that domestic substitution in the high-end segment still requires sustained efforts. At the clinical application level, the effectiveness of laser therapy is highly dependent on operator skill and precise parameter settings, with improper use potentially leading to complications such as thermal tissue damage and scarring, requiring manufacturers to provide systematic clinical training programs alongside hardware. On the regulatory compliance front, companies must simultaneously meet differentiated requirements such as FDA 510(k) and NMPA registration review guidelines, significantly extending the timeline for multi-region simultaneous launches.

Downstream Demand Trends

In the neurosurgery field, clinical study results for ClearPoint Neuro's Prism laser therapy system released in 2025 showed that among 14 glioblastoma patients, the system achieved a safe, reproducible treatment workflow with an average ablation time of just 6.5 minutes, with improved survival compared to the craniotomy control group. The company received FDA approval in September 2025 to extend Prism system compatibility to 1.5T MRI, significantly expanding its addressable market. In the epilepsy treatment field, the NMPA approved Hangzhou Jialiang Medical's MRI-monitored semiconductor laser therapy device in October 2025 for laser ablation treatment of drug-resistant focal epilepsy. In the urology field, Raykeen's thulium-doped fiber laser therapy device was included in the National High-end Medical Equipment Promotion and Application Project by the Ministry of Industry and Information Technology and the National Health Commission, with its Youlu Ziyou Xing® ultra-pulsed fiber thulium laser therapy device installed in multiple hospitals. High-intensity laser therapy has become the first-choice treatment for various conditions in ophthalmology and dermatology, while low-level laser therapy applications are extending from pain management and inflammation reduction toward chronic disease areas such as neurodegenerative disease prevention.

Regional Trends

North America, leveraging its mature clinical research system and responsive regulatory pathway, continues to lead the validation and translation of cutting-edge laser therapy technologies. The approval of Medtronic's Visualase™ V2 system in 2025 and ClearPoint Neuro's completion of clinical studies followed by expansion of MRI compatibility both demonstrate the region's innovation vitality in the neuro-laser therapy field. Europe maintains its advantage in basic research and clinical evidence accumulation, with the Prism system brain tumor clinical study completed at Skåne University Hospital in Sweden providing new support for the evidence-based medicine framework in European laser therapy. In the Asia-Pacific region, China is emerging as the most dynamic growth area for laser therapy devices. On the policy front, the NMPA issued registration review guidelines and approved domestic innovative products in 2025. On the enterprise front, local brand Raykeen topped the medical laser equipment brand index in May 2025, with its headquarters and medical laser equipment R&D and manufacturing facility topping out in October 2025, signaling that the domestic laser equipment industry is accelerating the development of full-chain capabilities from R&D to manufacturing. The domestic substitution rate for surgical equipment reached 77.7%, with Guangdong, Jiangsu, Shanghai, Zhejiang, and Beijing accounting for nearly 70% of total product registrations nationwide.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Laser Therapy Devices market?

What factors are driving Laser Therapy Devices market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Laser Therapy Devices market opportunities vary by end market size?

How does Laser Therapy Devices break out by Type, by Application?

This report presents a comprehensive overview of the global Laser Therapy Devices market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Solid-state Laser
• Gas Laser
• Fiber Lasers
• Semiconductor Laser

Segment by Wave Length

• Ultraviolet Lasers
• Visible Light Lasers
• Near Infrared Lasers
• Mid Infrared Lasers

Segment by Energy Output

• Continuous Wave Lasers
• Pulsed Lasers

Segment by Therapeutic Mechanism

• Photothermal Therapy
• Photochemical Therapy
• Photobiomodulation

Segment by Application

• Ophthalmology
• Dermatology
• Urology
• Neurosurgery

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Laser Therapy Devices market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Ophthalmology, Dermatology, Urology evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact